Compare Diamondback Energy Inc (FANG) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Diamondback Energy Inc vs Sanofi SA — how do they compare? Diamondback Energy Inc trades at $192.13 (market cap $53.67B), while Sanofi SA trades at $40.07 (market cap $95.18B). The key difference: Sanofi SA is the larger of the two by market cap, and Sanofi SA pays the higher dividend (6.01%). Which is the better fit depends on your goals — on Pluang, investors hold Diamondback Energy Inc for 69 Days and Sanofi SA for 94 Days on average.
| FANG | SNY | |
|---|---|---|
Market Cap | $53.67B | $95.18B |
Volume | 2,250,644 | 2,995,646 |
Sector | Energy | Health |
52-Week High | $213.69 | $52.34 |
52-Week Low | $137.29 | $39.51 |
Typical Hold Time | 69 Days | 94 Days |
Enterprise Value | $65.83B | $114.48B |
Dividend Yield | 2.3% | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Diamondback Energy (FANG) trades at $191.68, up 3.96% today, with strong analyst support (90.57% buy rating) and a $231.77 consensus price target. The stock shows bullish technical momentum above key support at $189, while fundamentals reveal robust revenue growth from $14.93B in 2025 to projected $17.0B in 2026, though net margins have compressed. Recent Q2 2026 earnings beat expectations at $6.48 EPS, and the company maintains solid cash flow generation with $8.76B from operations in 2025.
FANG presents a compelling growth opportunity with Permian Basin dominance and positive earnings momentum, but investors face risks from oil price volatility and insider selling. The stock's current valuation at 36.51 P/E requires sustained execution to justify upside, while technical indicators suggest near-term resistance at $193-197 levels.
Sanofi (SNY) trades at $40.23, up 0.07% with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported strong Q2 2026 earnings beat with EPS of $1.21 versus $1.10 expected, continuing a trend of exceeding expectations. Recent expansion of the immunology alliance with Regeneron adds potential for future growth through new antibody programs.
While valuation metrics appear reasonable with P/E of 22.14 and P/S of 1.77, projected 2026 net income decline to $4.0B (8.09% margin) raises concerns. Analyst consensus leans cautious with 44% buy ratings versus 52% hold, suggesting tempered optimism despite recent positive developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Diamondback Energy Inc
Diamondback Energy is an independent oil and gas producer in the United States. The company operates exclusively in the Permian Basin. At the end of 2021, the company reported net proven reserves of 1.8 billion barrels of oil equivalent. Net production averaged about 375,000 barrels per day in 2021, at a ratio of 60% oil, 20% natural gas liquids, and 20% natural gas.
Read more on FANG →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
